BIOSPAIN 2018 consolidates the congress as the 5th world biotechnology event

Paula Cañal
Oct 11, 2018

The Spanish Association of Biocompanies (ASEBIO) and the Regional Government of Andalusia have concluded the 9th edition of the International Meeting on Biotechnology BIOSPAIN 2018, which has broken attendance records and is crowned as the fifth world event on biotechnology.

During the inauguration of the congress, Ion Arocena, director of ASEBIO, wanted to highlight the improvement in attendance compared to the previous edition thanks to "a programme aligned with the industry's priorities". One of the main indicators of this success has been the number of meetings arranged by means of the partnering system used during the congress, with which about 4,500 meetings between attendees were calculated.

The Biotechnology Business Institute's team travelled to Seville to participate in the new edition of BIOSPAIN, an event to which it is assiduous. The directors of the center, Juan Garcia and Natalia Oñate, took the opportunity to publicize the activity of the center, networking and strength alliances with the Spanish and international biotech community.

The aim of this ninth edition has been "to enhance the value of the Spanish biotechnology ecosystem to investors and market players both nationally and internationally," explained the director of ASEBIO during the presentation of the event in Seville. In this sense, the congress brought together more than 600 companies from 30 countries, more than 200 exhibitors and almost 50 investors of great European relevance in Life Sciences. 

The main attendance that has highlighted in this edition has been the presence of the Top Ten of investment funds, that manage more than 8,000 million euros of assets in life sciences. Key players in the development of national biotechnology such as Ysios Capital Partners, Fund+, Johnson & Johnson Innovation, Kreos Capital Partners, Forbion Capital, Kreos Capital, Medicxi and M Ventures are some of the investors who attended the congress. 

To this participation is added the interest of the big names in the sector. For the first time, the major pharmaceutical companies took part in BIOSPAIN, including Johnson & Johnson, Lilly, MSD and Novartis. Big Pharma presented their development strategies in search of new alliances with biotech start-ups. "We have managed to turn it into the main platform for boosting international financing and business collaborations at the service of the Spanish biotech industry", added Arocena.

Once again, the biomedical area, agroalimentary and industrial biotechnology and access to financing were the central axis of the meeting. Other current topics, such as advanced therapies, biobanks, circular economy, artificial intelligence, genetic editing, immunotherapy, precision medicine and antibiotic resistance have been other subjects of interest throughout the congress.


Latest news

The Biotechnology Business Institute inaugurated the fifth edition of the master’s programs with the consolidation of its innovative educational model, Discover&Transfer

After the success of the first edition of the Discover&Transfer program, the new students of the Biotechnology Business Institute will develop new patents from the main research institutions of Barcelona.

The Biotechnology Business Institute signs a strategic collaboration agreement with IRB Barcelona, the Fundació Bosch i Gimpera and UPF, promoted by UPF Ventures, in a new educational model for drug discovery and technology transfer

The Biotechnology Business Institute (BBI) incorporates Discover & Transfer to the programs, where the students will be working with real drug candidates of these three institutions.

BIOSPAIN 2018 consolidates the congress as the 5th world biotechnology event

The ninth edition of the BIOSPAIN International Biotechnology Meeting, which ASEBIO organizes every two years, brought together more than 600 companies from 30 countries in the city of Seville.

The Summer Charity Cocktail supports companies researching in pediatric cancer, under the first Childhood Cancer Innovation Award

The charity event, organized by the Biotechnology Business Institute in collaboration with the Richi Childhood Cancer Foundation, raised money from the attendees to boost innovative companies researching in pediatric oncology.

Filter by category